What is Precise Bio?
Precise Bio is a pioneering entity specializing in the bio-fabrication of organs through an integrated 3D printing and tissue-engineering platform. Their innovative technology facilitates the scalable and repeatable production of bio-fabricated organs derived from a patient's own cells. This capability serves critical fields including cardiology, orthopedics, and ophthalmology, aiming to equip clinicians with cutting-edge tissue engineering science and proprietary bio-printing technology. The company targets healthcare professionals and institutions seeking advanced solutions in regenerative medicine.
How much funding has Precise Bio raised?
Precise Bio has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Precise Bio
PPP
Public-Private Partnership
What's next for Precise Bio?
With its large-scale late-stage funding, Precise Bio is strategically positioned for significant expansion and further development of its bio-fabrication technologies. The recent strategic investment suggests a strong validation of their approach and market potential, likely enabling the company to accelerate its research and development pipelines, scale production capabilities, and potentially forge new clinical partnerships. This capital infusion is expected to drive the company towards achieving its goal of revolutionizing organ transplantation and regenerative therapies.
See full Precise Bio company page
